Device Trial Radar · NCT05069558
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
May 9, 2022
Primary completion
Nov 30, 2025
Study completion Nov 2029
Sponsor
- Lead sponsor
- Occlutech International ABNot on our public-company list
- Sponsor type
- Industry
- First posted
- Oct 6, 2021
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO, prevention of recurrent embolic stroke, and device/procedure related Serious Adverse Events (SAE).
Conditions
- Stroke
- Patent Foramen Ovale
- PFO
Interventions
Investigational PFO Closure DeviceDevice
Occlutech Flex II PFO Closure Device
Standard of Care PFO Closure DeviceDevice
Amplatzer PFO Occluder and Gore Cardioform PFO Occluder
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effective Closure Rate of PFOTime frame: Twelve Months
Locations
48 sites in 8 countries. Site status is shown where the registry gives one.
Arizona Cardiovascular Research Center
Phoenix, Arizona
47 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.